Total Payments
$8,367
2024 Payments
$30.68
Companies
17
Transactions
248
Medicare Patients
663
Medicare Billing
$127,876
Payment Breakdown by Category
Food & Beverage$4,048 (48.4%)
Consulting$2,810 (33.6%)
Travel$1,452 (17.4%)
Education$56.99 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,048 | 242 | 48.4% |
| Consulting Fee | $2,810 | 1 | 33.6% |
| Travel and Lodging | $1,452 | 4 | 17.4% |
| Education | $56.99 | 1 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $5,491 | 54 | $0 (2021) |
| Janssen Biotech, Inc. | $697.82 | 65 | $0 (2021) |
| Allergan, Inc. | $577.84 | 51 | $0 (2020) |
| ViiV Healthcare Company | $464.88 | 32 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $243.47 | 9 | $0 (2021) |
| ABBVIE INC. | $224.71 | 9 | $0 (2024) |
| Insmed, Inc. | $216.12 | 11 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $122.16 | 1 | $0 (2017) |
| Theravance Biopharma, Inc. | $92.48 | 4 | $0 (2018) |
| Astellas Pharma US Inc | $79.95 | 5 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $30.68 | 1 | ABBVIE INC. ($30.68) |
| 2023 | $113.59 | 4 | AbbVie Inc. ($113.59) |
| 2021 | $307.55 | 17 | Insmed, Inc. ($93.42) |
| 2020 | $501.86 | 33 | Allergan, Inc. ($188.36) |
| 2019 | $849.91 | 72 | Janssen Biotech, Inc. ($174.36) |
| 2018 | $781.18 | 53 | Gilead Sciences, Inc. ($318.44) |
| 2017 | $5,782 | 68 | Gilead Sciences Inc ($4,924) |
All Payment Transactions
248 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/29/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $30.68 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/07/2023 | AbbVie Inc. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $27.89 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/06/2023 | AbbVie Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $26.57 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/03/2023 | AbbVie Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $27.22 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/06/2023 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $31.91 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/16/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.27 | General |
| 06/15/2021 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $20.26 | General |
| Category: Respiratory | ||||||
| 06/08/2021 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $14.80 | General |
| Category: Respiratory | ||||||
| 05/13/2021 | Janssen Biotech, Inc. | PREZCOBIX (Drug), PREZISTA | Food and Beverage | In-kind items and services | $16.25 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 05/12/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.04 | General |
| 05/11/2021 | Merck Sharp & Dohme Corporation | PIFELTRO (Drug), ISENTRESS, DIFICID | Food and Beverage | In-kind items and services | $15.93 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/10/2021 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $17.20 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/07/2021 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $25.89 | General |
| Category: Respiratory | ||||||
| 04/27/2021 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $17.20 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/07/2021 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $20.34 | General |
| Category: Respiratory | ||||||
| 04/06/2021 | Janssen Biotech, Inc. | PREZCOBIX (Drug), PREZISTA | Food and Beverage | In-kind items and services | $18.88 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 03/17/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $15.53 | General |
| 03/05/2021 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $19.32 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/01/2021 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $12.13 | General |
| Category: Respiratory | ||||||
| 02/09/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.86 | General |
| 01/22/2021 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $26.72 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/12/2021 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $13.93 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 12/28/2020 | VYERA PHARMACEUTICALS, LLC | Daraprim (Drug) | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: Toxoplasmosis | ||||||
| 12/16/2020 | Allergan, Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $16.17 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/10/2020 | Allergan, Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $3.75 | General |
| Category: ANTI-INFECTIVE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 6 | 228 | 445 | $88,540 | $37,485 |
| 2020 | 6 | 435 | 1,028 | $150,245 | $90,391 |
Total Patients
663
Total Services
1,473
Medicare Billing
$127,876
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 89 | 261 | $36,488 | $16,423 | 45.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 67 | 68 | $20,090 | $8,065 | 40.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 18 | 49 | $10,620 | $4,434 | 41.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 27 | 40 | $10,455 | $4,262 | 40.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 16 | 16 | $6,825 | $2,814 | 41.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 11 | 11 | $4,062 | $1,488 | 36.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 151 | 521 | $52,100 | $33,407 | 64.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 58 | 237 | $31,995 | $21,884 | 68.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 76 | 76 | $22,800 | $13,756 | 60.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 97 | 102 | $28,050 | $12,706 | 45.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 41 | 80 | $12,000 | $6,882 | 57.3% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 12 | 12 | $3,300 | $1,755 | 53.2% |
About Dr. H. Barry Baker, MD
Dr. H. Barry Baker, MD is a Infectious Disease healthcare provider based in Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/13/2005. The National Provider Identifier (NPI) number assigned to this provider is 1174527535.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. H. Barry Baker, MD has received a total of $8,367 in payments from pharmaceutical and medical device companies, with $30.68 received in 2024. These payments were reported across 248 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($4,048).
As a Medicare-enrolled provider, Baker has provided services to 663 Medicare beneficiaries, totaling 1,473 services with total Medicare billing of $127,876. Data is available for 2 years (2020–2021), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Miami, FL
- Active Since 06/13/2005
- Last Updated 10/04/2007
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1174527535
Products in Payments
- PREZCOBIX (Drug) $573.48
- DALVANCE (Drug) $520.51
- AVYCAZ (Drug) $282.04
- DOVATO (Drug) $271.60
- Arikayce (Drug) $216.12
- ZERBAXA (Drug) $156.01
- TRIUMEQ (Drug) $145.90
- Symtuza (Drug) $142.01
- Genvoya (Drug) $112.49
- Biktarvy (Drug) $110.34
- VIBATIV (Drug) $106.41
- Cresemba (Drug) $79.95
- JULUCA (Drug) $47.38
- SYMTUZA (Drug) $39.32
- CUBICIN RF (Drug) $29.77
- ISENTRESS (Drug) $27.94
- Daraprim (Drug) $19.10
- Xerava (Drug) $18.85
- CUTAQUIG (Biological) $17.21
- PREVNAR - 13 (Biological) $16.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Miami
Douglas Brust, M.d, M.D
Infectious Disease — Payments: $450,213
Infectious Disease $450,213
Ricardo Fonseca Franco
Infectious Disease — Payments: $135,298
Infectious Disease $135,298
Hector Bolivar, Md, MD
Infectious Disease — Payments: $105,997
Infectious Disease $105,997
Jorge Murillo, Md, MD
Infectious Disease — Payments: $85,760
Infectious Disease $85,760
Dushyantha Jayaweera, Md, MD
Infectious Disease — Payments: $79,219
Infectious Disease $79,219
Dr. Lilian Abbo, Md, MD
Infectious Disease — Payments: $69,205
Infectious Disease $69,205